0000000000067006

AUTHOR

Alexandra Russo

showing 21 related works from this author

Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recover…

2013

Treatment with exogenous von Willebrand factor (VWF) is indicated in patients with von Willebrand disease (VWD) in whom treatment with 1-deamino-8-d-arginine vasopressin/desmopressin is contraindicated. Wilate is a new generation plasma-derived concentrate of native VWF and coagulation factor VIII (FVIII) (in a physiological 1:1 ratio) developed for the treatment of VWD. This is the first study to report safety, efficacy and in vivo recovery (IVR) data from 15 paediatric patients less than 6 years of age who received Wilate for either prophylaxis, on-demand treatment or for treatment in surgical procedures during a prospective open-label trial (VWD type 1: 5, type 2A: 1, type 2B: 2, type 3:…

Malecongenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtyHemorrhageClinical studyVon Willebrand factorhemic and lymphatic diseasesvon Willebrand FactormedicineVon Willebrand diseaseHumansProspective StudiesChildDesmopressinGenetics (clinical)Paediatric patientsBleeding episodesFactor VIIIbiologyCoagulantsbusiness.industryInfantHematologyGeneral Medicinemedicine.diseasevon Willebrand DiseasesPhenotypeCoagulationTolerabilityChild Preschoolbiology.proteinFemalebusinessHalf-Lifemedicine.drugHaemophilia
researchProduct

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.

2017

Supplemental Digital Content is available in the text.

0301 basic medicineMaleCancer Researchmedicine.medical_treatmentT-LymphocytesEpitopes T-LymphocyteT-Cell Antigen Receptor SpecificityImmunotherapy AdoptiveEpitopeCohort StudiesExon0302 clinical medicineimmune system diseasesImmunology and AllergyMedicineProtein IsoformsChildAged 80 and overbiologyCD19CART-19B-ALLMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomaepitope-lossmedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisChild PreschoolComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFemaleClone (B-cell biology)Gene isoformAdultAdolescentRecombinant Fusion ProteinsImmunologyAntigens CD19Receptors Antigen T-CellCancer VaccinesCD1903 medical and health sciencesYoung AdultAntigenHumansAgedPharmacologybusiness.industryInfant NewbornisoformsInfantImmunotherapy030104 developmental biologyImmunologybiology.proteinClinical StudyTumor EscapeBone marrowbusinessJournal of immunotherapy (Hagerstown, Md. : 1997)
researchProduct

Tumor Lipids of Pediatric Papillary Renal Cell Carcinoma Stimulate Unconventional T Cells

2020

Papillary renal cell carcinoma (PRCC) is a rare entity in children with no established therapy protocols for advanced diseases. Immunotherapy is emerging as an important therapeutic tool for childhood cancer. Tumor cells can be recognized and killed by conventional and unconventional T cells. Unconventional T cells are able to recognize lipid antigens presented via CD1 molecules independently from major histocompatibility complex, which offers new alternatives for cancer immunotherapies. The nature of those lipids is largely unknown and α-galactosylceramide is currently used as a synthetic model antigen. In this work, we analyzed infiltrating lymphocytes of two pediatric PRCCs using flow cy…

Male0301 basic medicineT-Lymphocytesmedicine.medical_treatmentLymphocyte Activationlipid antigens0302 clinical medicineTumor MicroenvironmentImmunology and AllergyMedicinepediatric papillary renal cell carcinomaChildCells CulturedOriginal Researchmedicine.diagnostic_testbiologyKidney NeoplasmsPhenotypeChild PreschoolCD1DImmunohistochemistrylipids (amino acids peptides and proteins)Signal Transductionlcsh:Immunologic diseases. AllergyAdolescentImmunologyCD1Major histocompatibility complexCD1dPeripheral blood mononuclear cellFlow cytometry03 medical and health sciencesLymphocytes Tumor-InfiltratingAntigenParacrine CommunicationHumansTILsCarcinoma Renal CellCell Proliferationbusiness.industryInfantImmunotherapyLipid Metabolism030104 developmental biologyCase-Control StudiesCancer researchbiology.proteinAntigens CD1dbusinesslcsh:RC581-607unconventional T cells030215 immunologyFrontiers in Immunology
researchProduct

Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatri…

2017

Heritable predisposition is an important cause of cancer in children and adolescents. Although a large number of cancer predisposition genes and their associated syndromes and malignancies have already been described, it appears likely that there are more pediatric cancer patients in whom heritable cancer predisposition syndromes have yet to be recognized. In a consensus meeting in the beginning of 2016, we convened experts in Human Genetics and Pediatric Hematology/Oncology to review the available data, to categorize the large amount of information, and to develop recommendations regarding when a cancer predisposition syndrome should be suspected in a young oncology patient. This review su…

0301 basic medicineHistoryMedizinGene Expression0302 clinical medicineNeoplasm Proteins/geneticsNeoplasmsChildGenetics (clinical)Societies Medicalddc:618HematologyJuvenile myelomonocytic leukemiaCancer predispositionSyndromeFocus Groups21st Century3. Good healthNeoplasm Proteins030220 oncology & carcinogenesisHematologic NeoplasmsGenetic Testing/methodsmedicine.medical_specialtyAdolescentGenetics MedicalGenetic CounselingHistory 21st CenturyMedical/history/instrumentation/methodsFamilial adenomatous polyposis03 medical and health sciencesInternal medicineGeneticsmedicineHumansFocus Groups/methodsGenetic Predisposition to DiseaseGenetic TestingIntensive care medicineGenetic Counseling/ethicsbusiness.industryHematologic Neoplasms/diagnosis/genetics/pathologyCancermedicine.diseasePediatric cancerHuman genetics030104 developmental biologyLi–Fraumeni syndromeNeoplasms/diagnosis/genetics/pathologyMutationMedical/historySocietiesbusinessAmerican journal of medical genetics. Part A
researchProduct

49P Targeting IGF1R in osteosarcoma

2020

Oncologybusiness.industryCancer researchMedicineOsteosarcomaHematologybusinessmedicine.diseaseInsulin-like growth factor 1 receptorAnnals of Oncology
researchProduct

Radiation-induced vascular changes in the intracranial irradiation field in medulloblastoma survivors: An MRI study

2019

While survival times after treatment of medulloblastoma are increasing, little is known about radiochemotherapy (RCT)-induced cerebrovascular changes. High resolution vessel wall imaging (VWI) sequences are an emerging tool for the evaluation of cerebrovascular diseases. We performed VWI in medulloblastoma long-term survivors to screen for late sequelae of RCT.Twenty-two pediatric medulloblastoma survivors (mean age 25.8 years (10-53 years); 16.3 years (mean) post primary RCT (range 1-45 years)) underwent 2D VWI-MRI. Vessel wall thickening, contrast enhancement and luminal narrowing were analyzed. The findings were correlated with the patients' radiation protocols.Vessel wall changes were o…

Carotid Artery DiseasesMalemedicine.medical_specialtyAdolescentHigh resolutionRadiation induced030218 nuclear medicine & medical imaginglaw.invention03 medical and health sciences0302 clinical medicineCancer SurvivorsRandomized controlled triallawmedicine.arteryHumansMedicineRadiology Nuclear Medicine and imagingCerebellar NeoplasmsChildRadiation InjuriesMedulloblastomabusiness.industryMean ageHematologyCerebral ArteriesIntracranial Arteriosclerosismedicine.diseaseMagnetic Resonance ImagingOncologyCerebrovascular CirculationChild Preschool030220 oncology & carcinogenesisFemaleRadiologyThickeningCranial IrradiationInternal carotid arterybusinessCarotid Artery InternalMagnetic Resonance AngiographyAfter treatmentMedulloblastomaRadiotherapy and Oncology
researchProduct

Lysosomal storage disorder in non-immunological hydrops fetalis (NIHF) - more common than assumed? Report of four cases with transient NIHF and a rev…

2012

Abstract Background Lysosomal storage disorders (LSD) are a rare cause of non immunological hydrops fetalis (NIHF) and congenital ascites. The reported incidence is about 1%. The incidence of idiopathic NIHF is estimated to be about 18%. Patients and methods We report four cases with transient hydrops fetalis resulting from LSD and performed a literature review on LSD with NIHF and congenital ascites in combination. Results At present, 12 different LSDs are described to be associated with NIHF or congenital ascites. Most patients had a family history of NIHF, where the preceding sibling had not been examined. A diagnostic approach to the fetus with NIHF due to suspected LSD either in utero …

MalePathologymedicine.medical_specialtyHydrops FetalisNon-immunological hydrops fetalisPharmacology toxicologylcsh:MedicineLysosomal storage diseaseLysosomal storage disordersClinical approachPregnancyHydrops fetalisAscitesLysosomal storage diseaseHumansMedicineGenetics(clinical)Pharmacology (medical)Genetics (clinical)Medicine(all)business.industryResearchIncidence (epidemiology)lcsh:RTransient hydropsGeneral Medicinemedicine.diseaseCongenital ascitesLysosomal Storage DiseasesImmunologyFemalemedicine.symptombusinessOrphanet Journal of Rare Diseases
researchProduct

Susceptibility-weighted magnetic resonance imaging of cerebrovascular sequelae after radiotherapy for pediatric brain tumors

2017

Due to sensitive neuroimaging techniques, cerebrovascular complications such as cerebral microbleeds (CMB) and cerebral cavernous malformations (CCM) are increasingly recognized as considerable late effects after treatment for pediatric brain tumor. The aim of this study was to analyze CMB in a cohort of patients after cranial irradiation therapy for medulloblastoma or other pediatric brain tumors using susceptibility-weighted magnetic resonance imaging (SWI).Forty former pediatric brain tumor patients were enrolled in this prospective cross-sectional study and examined by cranial MRI including SWI sequences. Cerebral microbleeds, clinical symptoms and disability were evaluated.Thirty-six (…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentNeuroimagingCraniospinal IrradiationYoung Adult03 medical and health sciences0302 clinical medicineNeuroimagingmedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesChildRadiation InjuriesProspective cohort studyCerebral HemorrhageMedulloblastomamedicine.diagnostic_testBrain Neoplasmsbusiness.industryInfantMagnetic resonance imagingHematologymedicine.diseaseMagnetic Resonance ImagingRadiation therapyCross-Sectional StudiesOncologyCerebrovascular CirculationChild Preschool030220 oncology & carcinogenesisCohortDisease ProgressionFemaleRadiologyCranial IrradiationbusinessNeurocognitive030217 neurology & neurosurgeryRadiotherapy and Oncology
researchProduct

Identification of an Immunogenic Medulloblastoma-Specific Fusion Involving EPC2 and GULP1

2021

Medulloblastoma is the most common malignant brain tumor in children. Immunotherapy is yet to demonstrate dramatic results in medulloblastoma, one reason being the low rate of mutations creating new antigens in this entity. In tumors with low mutational burden, gene fusions may represent a source of tumor-specific neoantigens. Here, we reviewed the landscape of fusions in medulloblastoma and analyzed their predicted immunogenicity. Furthermore, we described a new in-frame fusion protein identified by RNA-Seq. The fusion involved two genes on chromosome 2 coding for the enhancer of polycomb homolog 2 (EPC2) and GULP PTB domain containing engulfment adaptor 1 (GULP1) respectively. By qRT-PCR …

MedulloblastomafusionCancer Researchmedulloblastoma; EPC2; GULP1; fusionImmunogenicityIn silicoGULP1Neoplasms. Tumors. Oncology. Including cancer and carcinogensBiologymedulloblastomamedicine.diseaseFusion proteinEPC2OncologyAntigenCancer researchmedicineCytotoxic T cellEnhancerRC254-282CD8Cancers
researchProduct

TRTH-08. HIGH GRADE NEUROEPITHELIAL TUMOR OF THE CENTRAL NERVOUS SYSTEM WITH BCOR ALTERATION IS SENSITIVE TO IGF1R INHIBITION

2017

High grade neuroepithelial tumor of the central nervous system with BCOR alteration (CNS HGNET-BCOR) is a recently described new tumor entity which was formerly diagnosed with diverse histological diagnoses, for example as ependymoma. This tumor predominantly affects children and has a dismal prognosis. No standard therapies for this entity exist so far. Recently we described the activation of the Sonic hedgehog (SHH) and the WNT signaling pathway in this tumor and described a primary cell culture (PhKh1) isolated from a skull metastasis of a seven years old patient. We also detected a high expression of IGF2, which is known to be required for SHH signaling in medulloblastoma. IGF2 signals …

MedulloblastomaEpendymomaCancer Researchanimal structuresCell growthCentral nervous systemWnt signaling pathwayBiologymedicine.diseaseNeuroepithelial cellAbstractsmedicine.anatomical_structureOncologyCell culturemedicineCancer researchNeurology (clinical)Insulin-like growth factor 1 receptor
researchProduct

Human toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancy.

2006

Toll-like receptor 4 (TLR4) is required for efficient recognition of bacterial infections. We investigated an association between 2 TLR4 mutations (Asp 299 Gly and Thr 399 Ile) and meningococcal disease in 197 patients and 214 healthy controls by allele-specific real time polymerase chain reaction and direct sequencing. Although the allele frequency was not higher in the overall patient population, a significantly higher frequency in the 40 patients younger than 12 months of age (P = 0.007) was observed. We conclude that TLR4 mutations represent a risk factor for meningococcal disease in this age group.

Microbiology (medical)MaleMutation MissenseMeningococcal diseasemedicine.disease_causePolymerase Chain ReactionGene FrequencyMedicineHumansGenetic Predisposition to DiseaseRisk factorReceptorChildAllele frequencyAllelesToll-like receptorMutationbusiness.industryAge FactorsInfantDNASequence Analysis DNAmedicine.diseaseEuropeMeningococcal InfectionsToll-Like Receptor 4Infectious DiseasesReal-time polymerase chain reactionAmino Acid SubstitutionChild PreschoolPediatrics Perinatology and Child HealthImmunologyTLR4FemalebusinessThe Pediatric infectious disease journal
researchProduct

Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological…

2018

Ependymoma with YAP1-MAMLD1 fusion is a rare, recently described supratentorial neoplasm of childhood, with few cases published so far. We report on 15 pediatric patients with ependymomas carrying YAP1-MAMLD1 fusions, with their characteristic histopathology, immunophenotype and molecular/cytogenetic, radiological and clinical features. The YAP1-MAMLD1 fusion was documented by RT-PCR/Sanger sequencing, and tumor genomes were studied by molecular inversion probe (MIP) analysis. Significant copy number alterations were identified by GISTIC (Genomic Identification of Significant Targets in Cancer) analysis. All cases showed similar histopathological features including areas of high cellularity…

0301 basic medicineEpendymomaSanger sequencingPathologymedicine.medical_specialtybusiness.industryGeneral NeuroscienceSupratentorial NeoplasmLocus (genetics)medicine.diseaseMolecular Inversion ProbePathology and Forensic Medicine03 medical and health sciencessymbols.namesake030104 developmental biology0302 clinical medicineImmunophenotypingmedicinesymbolsHistopathologyNeurology (clinical)medicine.symptombusinessAnaplasia030217 neurology & neurosurgeryBrain Pathology
researchProduct

Radical surgery and different types of urinary diversion in patients with rhabdomyosarcoma of bladder or prostate--a single institution experience.

2013

Abstract Purpose In a retrospective study we analyzed the outcome of patients treated for rhabdomyosarcoma (RMS) of the bladder/prostate with special attention to radical surgery. Methods In 25 patients with genitourinary RMS (15 bladder/10 prostate) the median age at diagnosis was 4 years [1] , [2] , [3] , [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , and 8 patients had a stage II RMS, 12 stage III and 5 stage IV. In 19/25 (12 bladder/7 prostate), radical surgery and urinary diversion were performed. Urinary diversion comprised 2 continent anal diversions, 11 continent cutaneous diversions, 4 colon conduits and 2 urethral diversions (2 +…

AdultMalemedicine.medical_specialtyAdolescentUrologymedicine.medical_treatmentUrologyAnal CanalUrinary DiversionYoung AdultAntineoplastic Combined Chemotherapy ProtocolsRhabdomyosarcomaMedicineHumansRadical surgeryRhabdomyosarcomaChildCyclophosphamideRetrospective Studiesbusiness.industryGenitourinary systemUrinary diversionUrinary Reservoirs ContinentProstatic NeoplasmsSurgical Stomasmedicine.diseaseAppendixNeck of urinary bladdermedicine.anatomical_structureTreatment OutcomeUrinary Bladder NeoplasmsDoxorubicinVincristineChild PreschoolPediatrics Perinatology and Child HealthDactinomycinFemalePouchNeoplasm Recurrence LocalbusinessComplicationhuman activitiesFollow-Up StudiesJournal of pediatric urology
researchProduct

Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma

2021

Simple Summary Osteosarcoma, Ewing’s sarcoma, and H3K27M-mutant diffuse midline glioma are rare but aggressive malignancies occurring mainly in children. Due to their rareness and often fatal course, drug development is challenging. Here, we repurposed the existing drugs dinutuximab and eliglustat and investigated their potential to directly target or indirectly modulate the tumor cell-specific ganglioside GD2. Our data suggest that targeting and/or modulating tumor cell-specific GD2 may offer a new therapeutic strategy for the above mentioned tumor entities. Abstract The ganglioside GD2 is an important target in childhood cancer. Nevertheless, the only therapy targeting GD2 that is approve…

0301 basic medicineCancer Researchlcsh:RC254-282Article03 medical and health sciences0302 clinical medicineNeuroblastomaGliomaosteosarcomaH3K27M-mutant diffuse midline gliomamedicineGangliosidegangliosidebusiness.industrydinutuximabDinutuximabEwing's sarcomaCancerGD2eliglustatlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncologyganglioside; GD2; dinutuximab; eliglustat; miglustat; H3K27M-mutant diffuse midline glioma; Ewing’s sarcoma; osteosarcoma030220 oncology & carcinogenesisCancer researchmiglustatSarcomaEwing’s sarcomabusinessEliglustatCancers; Volume 13; Issue 3; Pages: 520
researchProduct

PNR-35CNS HGNET-BCOR - MOLECULAR CHARACTERIZATION AND IDENTIFICATION OF POSSIBLE THERAPEUTIC TARGETS OF A NEW BRAIN TUMOR ENTITY

2016

0106 biological sciences0301 basic medicineCancer Researchbusiness.industryBrain tumorComputational biologymedicine.disease01 natural sciencesAbstracts03 medical and health sciences030104 developmental biologyText miningOncology010608 biotechnologymedicineNeurology (clinical)Identification (psychology)businessNeuro-Oncology
researchProduct

Skeletal abnormalities of the upper limbs--neonatal diagnosis of 49,XXXXY syndrome.

2012

A case of neonatal diagnosis of 49,XXXXY syndrome is presented. Clinical identification was prompted by a bilateral thickening of the radioulnar joints and X-ray imaging disclosing almost complete radioulnar synostosis. Conventional karyotyping was initiated and revealed a karyotype of 49,XXXXY. Previously reported neonatal symptoms such as low birth weight, muscular hypotonia, or genital malformations were absent in this case. Microsatellite analysis showed two different X chromosomes each present in two copies, supporting that the four X chromosomes had arisen from a nondisjunction in maternal meiosis I followed by a second nondisjunction involving both X chromosomes in meiosis II. Multid…

MalePediatricsmedicine.medical_specialtyBiologyUpper ExtremityNeonatal ScreeningMeiosisGeneticsmedicineHumansAbnormalities MultipleMuscle SkeletalX chromosomeChromosomes Human XMuscular hypotoniaMeiosis IIInfant NewbornKaryotypeGeneral MedicineAnatomySyndromemedicine.diseaseLow birth weightNondisjunction49 XXXXY syndromemedicine.symptomGene
researchProduct

16P Molecular analysis for precision oncology of children: Beyond genomics

2020

medicine.medical_specialtyOncologyPrecision oncologybusiness.industrymedicineGenomicsMedical physicsHematologybusinessMolecular analysisAnnals of Oncology
researchProduct

A New Algorithm and Panel Construction for Pediatric Leukemia Immunophenotyping Using 10-Color Flow Cytometry

2012

Abstract Abstract 4799 Background: Rapid identification and quantification of abnormal cell populations in minimal specimen are crucial for diagnosis and longitudinal minimal residual disease (MRD) testing of childhood leukemia. So far, most standard immunophenotypic analyses are performed using antibody panels with up to five-colors and require high cell numbers. For infant and pediatric specimen, high-level multicolor analyses is highly desirable to gather sufficient data for initial diagnostic and follow up monitoring of pathologic populations. Objective: In this study, we aimed to establish a newly defined pediatric multicolor flow cytometric panel algorithm with high reliability yet mi…

Pediatric leukemiamedicine.diagnostic_testChildhood leukemiabusiness.industrymedicine.drug_classImmunologyCell BiologyHematologyMonoclonal antibodymedicine.diseaseBiochemistryMinimal residual diseaseFlow cytometryImmunophenotypingMedicineStage (cooking)businessCytometryAlgorithmBlood
researchProduct

Results of a Prospective, Open-Label Trial to Assess the Efficacy, Safety and Immunogenicity of Wilate® in Children Under 6 Years of Age with Inherit…

2011

Abstract Abstract 3330 Introduction: Wilate® is a new-generation plasma-derived concentrate of von Willebrand factor (VWF) and factor VIII (FVIII) developed for treatment of patients with von Willebrand disease (VWD) and haemophilia A. The objective of this study was to assess efficacy, safety and immunogenicity of Wilate in children below 6 years of age with inherited VWD. Methods: The prospective, multi-centre trial included patients with inherited VWD of any type below 6 years of age with insufficient response to DDAVP. Any clinical event requiring VWF/FVIII concentrate treatment within 1 year was treated with Wilate. Efficacy was recorded by using a 4-point VRS and in vivo recovery of F…

congenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsbiologybusiness.operationbusiness.industryImmunogenicityImmunologyCell BiologyHematologyHaemophiliamedicine.diseaseOctapharmaBiochemistryVon Willebrand factorTolerabilityhemic and lymphatic diseasesInternal medicinemedicinebiology.proteinVon Willebrand diseaseDosingbusinessAdverse effectBlood
researchProduct

Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC

2020

Background: Careful assessment of bleeding history is the first step in the evaluation of patients with mild/moderate bleeding disorders, and the use of a bleeding assessment tool (BAT) is strongly encouraged. Although a few studies have assessed the utility of the ISTH-BAT in patients with inherited platelet function disorders (IPFD) none of them was sufficiently large to draw conclusions and/or included appropriate control groups. Objectives: The aim of the present study was to test the utility of the ISTH-BAT in a large cohort of patients with a well-defined diagnosis of inherited platelets disorder in comparison with two parallel cohorts, one of patients with type-1 von Willebrand disea…

bleeding assessment toolSYMPTOMSMedicina Clínica030204 cardiovascular system & hematologyBLEEDING DISORDERS0302 clinical medicinePlateletINHERITED PLATELET DISORDERSUTILITYRISKbleeding disordersCommunicationbleeding assessment tool; bleeding diathesis; bleeding disorders; inherited platelet disorders; plateletsbleeding diathesisHematologyPLATELETSvon Willebrand DiseasesplateletsBLEEDING DIATHESISLife Sciences & BiomedicineVON-WILLEBRAND-DISEASEmedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDPlatelet Function TestsPlatelet disorderQUESTIONNAIREinherited platelet disorderHemorrhageDIAGNOSIS03 medical and health sciencesInternal medicineSCOREmedicineVon Willebrand diseaseHumansHematologíaIn patientbleeding disorderBLEEDING ASSESSMENT TOOLScience & Technologybleeding diathesibusiness.industrySettore MED/09 - MEDICINA INTERNAMILDmedicine.diseaseLarge cohortBleeding diathesisPeripheral Vascular Diseaseinherited platelet disordersCardiovascular System & CardiologyBlood Platelet Disordersbusiness
researchProduct

Hemophagocytic Lymphohistiocytosis in Early Infancy- Pitfall of Differentiation between Hereditary and Infectious Reasons

2018

Abstract Hemophagocytic Lymphohistiocytosis (HLH) is characterized by pathologic immune activation which occurs either as a familial disorder or as an acquired condition. The diagnosis of HLH requires the presence of five out of nine criteria: fever, splenomegaly, pancytopenia, hypertriglyceridemia, hypofibrinogenemia, hemophagocytosis in bone marrow, hyperferritinemia, low or absent natural killer cell activity and high level of soluble interleukin-2 receptor. Here we present a 6-month-old girl with parents from Southern Italy. She suffered from hepatosplenomegaly and a recurrent high fever for 3 months' duration. On admission, she showed neurological symptoms including irritability and ne…

Hemophagocytic lymphohistiocytosisPediatricsmedicine.medical_specialtybusiness.operationbusiness.industryImmunologyHepatosplenomegalyCell BiologyHematologyFamilial Hemophagocytic Lymphohistiocytosismedicine.diseaseOctapharmaBiochemistryPancytopeniaVisceral leishmaniasisMacrophage activation syndromemedicineHemophagocytosismedicine.symptombusinessBlood
researchProduct